Feb 2026· Clinical and Experimental Rheumatology· 0 citations· 32 references
Medicine
TL;DR
The decreased PD-1 expression on CD8+T cells, along with the decreased PD-1, TIM-3 and TIGIT responses of CD8+T cells upon IFN-I stimulation, demonstrated an altered immune response in Behçet's disease.
Abstract
Objectives
Programmed cell death-1 (PD-1) protein on CD8+T cells may affect disease development as a regulatory molecule through various mechanisms. On the other hand, type-I interferons (IFN-I) are used in autoimmune and autoinflammatory diseases to induce regulatory mechanisms. This study aims to investigate PD-1 molecules on CD8+T cells in Behçet's disease (BD) and their response to IFN-I.
Methods
BD (n=37) patients were compared with age- and sex-matched healthy (n=24) and diseased controls (n=29). Peripheral mononuclear cells (PBMCs) were stained for PD-1, CD45RA and CCR7 molecules on CD3+CD8+T cells. Cells from patients and controls were further activated in vitro by anti-CD3 and interferon (IFN-α/2α1b) and the induction of PD-1, TIM-3 and TIGIT on CD8+T cells was analysed.
Results
PD-1 on CD8+T cells with potentially regulatory functions were significantly lower in BD patients, regardless of disease activity, than in controls. CD3 stimulation of PBMCs induced PD-1 expression in all groups, whereas the addition of interferon to stimulated CD8+T cells produced differential responses: the increase of PD-1 on CD8+T cells in controls was not observed in BD patients. The responsive increase of similar co-inhibitory molecules, TIM-3 and TIGIT, in controls was not seen in BD patients either.
Conclusions
The decreased PD-1 expression on CD8+T cells, along with the decreased PD-1, TIM-3 and TIGIT responses of CD8+T cells upon IFN-I stimulation, demonstrated an altered immune response in BD.
BACKGROUND
CAR-T cell therapy (Chimeric Antigen Receptor T cells) is a promising approach for immune-mediated inflammatory diseases (IMIDs). Plasmacytoid dendritic cells (pDCs), which infiltrate tissues and secrete type I interferons (IFN-I), play a central early role in IMIDs and represent an attractive therapeutic ta...
B. Caël, E. Bôle-Richard, Imane Belakri et al.· Journal of Allergy and Clini...· 0 citations
Programmed cell death protein 1 (PD-1) is expressed by T cells during progressive multifocal leukoencephalopathy (PML), a life-threatening brain disease caused by the human-only JC polyomavirus (JCPyV). PD-1 checkpoint immunotherapy has benefited some PML patients, but reasons for its variable outcomes are unclear. Usi...
Arrienne B. Butic, E. Afanasiev, Samantha A. Spencer et al.· Nature Communications· 0 citations
Abatacept selectively modulates CD319/SLAMF7-expressing cytotoxic T cells and suppresses associated pro-fibrotic and pro-inflammatory cytokines, particularly in the fibroproliferative subtype, where CD319+ T cell reductions correlate with clinical improvement.
Mikel Gurrea-Rubio, Laura A. Cooney, Kohei Maeda et al.· Arthritis & Rheumatology· 0 citations
The COVID‐19 pandemic has created a global health challenge. Severe cases are associated with immune system dysfunction, which can lead to uncontrolled inflammation. There are no published data on the specific roles of natural killer (NK)‐cell subsets and immune checkpoint (IC) molecules in disease severity. Thirty‐fiv...
M. Meggyes, Dávid U. Nagy, Ildiko Toth et al.· Journal of Immunological Res...· 0 citations
Findings support a heterogeneous and dynamic immune profile in AA and highlight the importance of multivariate approaches in identifying independent immunological correlates.
Hatice Türk Dağı, H. Özdemir, Mehmet Akyürek et al.· Turkish Journal of Medical S...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.